MX2021005484A - Composiciones de conjugados de anticuerpo-farmaco que contienen duocarmicina filtrable y metodos relacionados. - Google Patents

Composiciones de conjugados de anticuerpo-farmaco que contienen duocarmicina filtrable y metodos relacionados.

Info

Publication number
MX2021005484A
MX2021005484A MX2021005484A MX2021005484A MX2021005484A MX 2021005484 A MX2021005484 A MX 2021005484A MX 2021005484 A MX2021005484 A MX 2021005484A MX 2021005484 A MX2021005484 A MX 2021005484A MX 2021005484 A MX2021005484 A MX 2021005484A
Authority
MX
Mexico
Prior art keywords
duocarmycin
filterable
drug conjugate
related methods
containing antibody
Prior art date
Application number
MX2021005484A
Other languages
English (en)
Inventor
Den Hoef Carolus Johannes Edgar Van
Original Assignee
Byondis Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Byondis Bv filed Critical Byondis Bv
Publication of MX2021005484A publication Critical patent/MX2021005484A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Los conjugados de fármaco-anticuerpo basados en duocarmicina se pueden separar fácilmente del fármaco-enlazador de duocarmicina no conjugado en una composición que contiene un sistema de solventes de agua y acetonitrilo y que tiene de 30% a 60% de acetonitrilo.
MX2021005484A 2018-11-09 2019-11-04 Composiciones de conjugados de anticuerpo-farmaco que contienen duocarmicina filtrable y metodos relacionados. MX2021005484A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18205459 2018-11-09
PCT/EP2019/080084 WO2020094561A1 (en) 2018-11-09 2019-11-04 Filterable duocarmycin-containing antibody-drug conjugate compositions and related methods

Publications (1)

Publication Number Publication Date
MX2021005484A true MX2021005484A (es) 2021-06-18

Family

ID=64270729

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021005484A MX2021005484A (es) 2018-11-09 2019-11-04 Composiciones de conjugados de anticuerpo-farmaco que contienen duocarmicina filtrable y metodos relacionados.

Country Status (21)

Country Link
US (1) US20210386867A1 (es)
EP (1) EP3876997B1 (es)
JP (1) JP2022506860A (es)
KR (1) KR20210091752A (es)
CN (1) CN112969478B (es)
AU (1) AU2019376457A1 (es)
BR (1) BR112021008293A2 (es)
CA (1) CA3118788A1 (es)
CL (1) CL2021001199A1 (es)
DK (1) DK3876997T3 (es)
ES (1) ES2926980T3 (es)
HR (1) HRP20221197T1 (es)
HU (1) HUE059919T2 (es)
IL (1) IL282913B1 (es)
LT (1) LT3876997T (es)
MX (1) MX2021005484A (es)
PL (1) PL3876997T3 (es)
PT (1) PT3876997T (es)
SG (1) SG11202104413TA (es)
WO (1) WO2020094561A1 (es)
ZA (1) ZA202102798B (es)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI412367B (zh) 2006-12-28 2013-10-21 Medarex Llc 化學鏈接劑與可裂解基質以及其之綴合物
CN102317283A (zh) 2008-11-03 2012-01-11 辛塔佳股份有限公司 新型cc-1065类似物及其缀合物
MX336853B (es) 2010-04-21 2016-01-19 Syntarga Bv Conjugados novedosos de analogos cc-1065 y ligaduras bifuncionales.
RU2016117810A (ru) * 2013-10-11 2017-11-17 Асана Биосайенсис, Ллк Конъюгаты белок-полимер-лекарственное средство
CA2935077C (en) 2013-12-27 2022-03-15 Geoffrey C. Winters Sulfonamide-containing linkage systems for drug conjugates
AU2015205509B2 (en) * 2014-01-10 2019-08-15 Byondis B.V. Duocarmycin ADCs showing improved in vivo antitumor activity
US10407743B2 (en) 2014-05-22 2019-09-10 Synthon Biopharmaceuticals B.V. Site-specific conjugation of linker drugs to antibodies and resulting ADCs
CN106458892B (zh) * 2014-06-05 2019-10-18 斯索恩生物制药有限公司 用于制备倍癌霉素前药的改进方法
AU2016292759B2 (en) * 2015-07-10 2021-05-20 Byondis B.V. Compositions comprising antibody-duocarmycin drug conjugates
ES2854298T3 (es) * 2015-09-22 2021-09-21 Byondis Bv Tratamiento con SYD985 de pacientes con cáncer resistentes a T-DM1
JP6412906B2 (ja) * 2015-11-03 2018-10-24 財團法人工業技術研究院Ｉｎｄｕｓｔｒｉａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 化合物、リンカー−薬物およびリガンド−薬物複合体

Also Published As

Publication number Publication date
US20210386867A1 (en) 2021-12-16
JP2022506860A (ja) 2022-01-17
ZA202102798B (en) 2022-08-31
SG11202104413TA (en) 2021-05-28
PL3876997T3 (pl) 2022-12-19
CN112969478A (zh) 2021-06-15
KR20210091752A (ko) 2021-07-22
CA3118788A1 (en) 2020-05-14
AU2019376457A1 (en) 2021-05-27
HUE059919T2 (hu) 2023-01-28
WO2020094561A1 (en) 2020-05-14
BR112021008293A2 (pt) 2021-08-03
EP3876997A1 (en) 2021-09-15
IL282913A (en) 2021-06-30
ES2926980T3 (es) 2022-10-31
LT3876997T (lt) 2022-11-10
HRP20221197T1 (hr) 2022-12-09
CL2021001199A1 (es) 2021-12-17
DK3876997T3 (da) 2022-09-26
CN112969478B (zh) 2023-10-27
IL282913B1 (en) 2024-03-01
PT3876997T (pt) 2022-11-11
EP3876997B1 (en) 2022-08-03

Similar Documents

Publication Publication Date Title
WO2020236825A8 (en) Mcl-1 inhibitor antibody-drug conjugates and methods of use
PE20161211A1 (es) Anticuerpos y conjugados de anticuerpo y farmaco anti-egfr
WO2016064749A3 (en) Antibody-drug conjugates and related compounds, compositions, and methods of use
MY189113A (en) Eribulin-based antibody-drug conjugates and methods of use
PH12016501711A1 (en) Anti-her3 antibody-drug conjugate
MX2019012676A (es) Derivados de 2-aminoquinolina.
MX2021015427A (es) Vesiculas extracelulares microbianas procesadas.
NZ741261A (en) Pyrrolobenzodiazepine antibody drug conjugates and methods of use
PH12020500672A1 (en) Splicing modulators antibody-drug conjugates
PH12016500904B1 (en) Anti-her2 antibody-drug conjugate
WO2018124512A3 (ko) 압타머-약물 콘쥬게이트 및 그 용도
MX337408B (es) Formulaciones topicas que tienen biodisponibilidad aumentada.
MX2009007784A (es) Composiciones de tiacumicinas estables.
JOP20210045A1 (ar) مترافقات جسم مضاد وعقار هربوكسيديين وطرق استخدامها
NZ742916A (en) C-terminal lysine conjugated immunoglobulins
MX2019009418A (es) Formulaciones de combinacion del triplete y metodos para tratar o reducir el riesgo de enfermedad cardiovascular.
CA3198996A1 (en) Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
MX2020003089A (es) Analogos de tailanstatina.
IL302122A (en) Antibody-drug conjugation and its application
AR118625A1 (es) Composición cosmética tópica y usos de la misma
MX2021005484A (es) Composiciones de conjugados de anticuerpo-farmaco que contienen duocarmicina filtrable y metodos relacionados.
FR3073142B1 (fr) Formulation cosmetique
MX2022003398A (es) Composicion micelar inmunoestimulante.
IL307282A (en) Antidote conjugates against HER2 and their applications
MX2020012714A (es) Composiciones y metodos para aumentar el consumo de agua en los animales de compa?ia.